322 related articles for article (PubMed ID: 34277638)
1. Boosting Antitumor Response by Costimulatory Strategies Driven to 4-1BB and OX40 T-cell Receptors.
Mascarelli DE; Rosa RSM; Toscaro JM; Semionatto IF; Ruas LP; Fogagnolo CT; Lima GC; Bajgelman MC
Front Cell Dev Biol; 2021; 9():692982. PubMed ID: 34277638
[TBL] [Abstract][Full Text] [Related]
2. Costimulation of T cells by OX40, 4-1BB, and CD27.
Croft M
Cytokine Growth Factor Rev; 2003; 14(3-4):265-73. PubMed ID: 12787564
[TBL] [Abstract][Full Text] [Related]
3. Cross-talk between 4-1BB and TLR1-TLR2 Signaling in CD8+ T Cells Regulates TLR2's Costimulatory Effects.
Joseph AM; Srivastava R; Zabaleta J; Davila E
Cancer Immunol Res; 2016 Aug; 4(8):708-16. PubMed ID: 27267778
[TBL] [Abstract][Full Text] [Related]
4. High levels of costimulatory receptors OX40 and 4-1BB characterize CD4+CD28null T cells in patients with acute coronary syndrome.
Dumitriu IE; Baruah P; Finlayson CJ; Loftus IM; Antunes RF; Lim P; Bunce N; Kaski JC
Circ Res; 2012 Mar; 110(6):857-69. PubMed ID: 22282196
[TBL] [Abstract][Full Text] [Related]
5. Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses.
Lee SW; Park Y; Song A; Cheroutre H; Kwon BS; Croft M
J Immunol; 2006 Oct; 177(7):4464-72. PubMed ID: 16982882
[TBL] [Abstract][Full Text] [Related]
6. OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases.
Pan PY; Zang Y; Weber K; Meseck ML; Chen SH
Mol Ther; 2002 Oct; 6(4):528-36. PubMed ID: 12377195
[TBL] [Abstract][Full Text] [Related]
7. 4-1BB costimulation promotes bystander activation of human CD8 T cells.
Reithofer M; Rosskopf S; Leitner J; Battin C; Bohle B; Steinberger P; Jahn-Schmid B
Eur J Immunol; 2021 Mar; 51(3):721-733. PubMed ID: 33180337
[TBL] [Abstract][Full Text] [Related]
8. The expression and the regulatory role of OX40 and 4-1BB heterodimer in activated human T cells.
Ma BY; Mikolajczak SA; Danesh A; Hosiawa KA; Cameron CM; Takaori-Kondo A; Uchiyama T; Kelvin DJ; Ochi A
Blood; 2005 Sep; 106(6):2002-10. PubMed ID: 15941918
[TBL] [Abstract][Full Text] [Related]
9. 4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function.
Lee SJ; Myers L; Muralimohan G; Dai J; Qiao Y; Li Z; Mittler RS; Vella AT
J Immunol; 2004 Sep; 173(5):3002-12. PubMed ID: 15322159
[TBL] [Abstract][Full Text] [Related]
10. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.
Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH
J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies.
Chester C; Sanmamed MF; Wang J; Melero I
Blood; 2018 Jan; 131(1):49-57. PubMed ID: 29118009
[TBL] [Abstract][Full Text] [Related]
12. A mathematical model of combined CD8 T cell costimulation by 4-1BB (CD137) and OX40 (CD134) receptors.
Konstorum A; Vella AT; Adler AJ; Laubenbacher RC
Sci Rep; 2019 Jul; 9(1):10862. PubMed ID: 31350431
[TBL] [Abstract][Full Text] [Related]
13. Agonist antibodies to TNFR molecules that costimulate T and NK cells.
Melero I; Hirschhorn-Cymerman D; Morales-Kastresana A; Sanmamed MF; Wolchok JD
Clin Cancer Res; 2013 Mar; 19(5):1044-53. PubMed ID: 23460535
[TBL] [Abstract][Full Text] [Related]
14. 4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses.
Dawicki W; Bertram EM; Sharpe AH; Watts TH
J Immunol; 2004 Nov; 173(10):5944-51. PubMed ID: 15528328
[TBL] [Abstract][Full Text] [Related]
15. Critical, but conditional, role of OX40 in memory T cell-mediated rejection.
Vu MD; Clarkson MR; Yagita H; Turka LA; Sayegh MH; Li XC
J Immunol; 2006 Feb; 176(3):1394-401. PubMed ID: 16424166
[TBL] [Abstract][Full Text] [Related]
16. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses.
Shuford WW; Klussman K; Tritchler DD; Loo DT; Chalupny J; Siadak AW; Brown TJ; Emswiler J; Raecho H; Larsen CP; Pearson TC; Ledbetter JA; Aruffo A; Mittler RS
J Exp Med; 1997 Jul; 186(1):47-55. PubMed ID: 9206996
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Efficacy of 4-1BB Costimulation Is Abrogated by PD-1 Blockade in a Model of Spontaneous B-cell Lymphoma.
McKee SJ; Doff BL; Soon MS; Mattarollo SR
Cancer Immunol Res; 2017 Mar; 5(3):191-197. PubMed ID: 28115358
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas.
Gruss HJ; Dower SK
Blood; 1995 Jun; 85(12):3378-404. PubMed ID: 7780126
[TBL] [Abstract][Full Text] [Related]
19. BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models.
Jiang B; Zhang T; Deng M; Jin W; Hong Y; Chen X; Chen X; Wang J; Hou H; Gao Y; Gong W; Wang X; Li H; Zhou X; Feng Y; Zhang B; Jiang B; Lu X; Zhang L; Li Y; Song W; Sun H; Wang Z; Song X; Shen Z; Liu X; Li K; Wang L; Liu Y
Front Med; 2023 Dec; 17(6):1170-1185. PubMed ID: 37747585
[TBL] [Abstract][Full Text] [Related]
20. Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy.
Li W; Zhang X; Zhang C; Yan J; Hou X; Du S; Zeng C; Zhao W; Deng B; McComb DW; Zhang Y; Kang DD; Li J; Carson WE; Dong Y
Nat Commun; 2021 Dec; 12(1):7264. PubMed ID: 34907171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
